Enveric Biosciences, Inc. (NASDAQ:ENVB) Short Interest Update

Enveric Biosciences, Inc. (NASDAQ:ENVB) was the recipient of a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 152,100 shares, a decline of 43.4% from the June 15th total of 268,800 shares. Based on an average trading volume of 470,600 shares, the short-interest ratio is currently 0.3 days. Approximately 2.0% of the shares of the company are sold short.

Institutional Investors Weigh In On Enveric Biosciences

A hedge fund recently bought a new stake in Enveric Biosciences stock. Virtu Financial LLC purchased a new stake in Enveric Biosciences, Inc. (NASDAQ:ENVB) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 33,835 shares of the company’s stock, valued at approximately $34,000. Virtu Financial LLC owned approximately 0.44% of Enveric Biosciences at the end of the most recent reporting period. 13.82% of the stock is owned by institutional investors and hedge funds.

Enveric Biosciences Trading Up 2.6 %

Shares of NASDAQ:ENVB traded up $0.01 during trading on Friday, reaching $0.52. The company had a trading volume of 135,334 shares, compared to its average volume of 2,299,026. The stock’s fifty day moving average price is $0.73 and its 200 day moving average price is $0.94. Enveric Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $3.90.

Enveric Biosciences (NASDAQ:ENVB) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.61) EPS for the quarter, hitting analysts’ consensus estimates of ($0.61). Equities analysts anticipate that Enveric Biosciences will post -1.98 EPS for the current year.

About Enveric Biosciences

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.